Publications

Emperumal CP, Villa A, Hwang C, Oh D, Fong L, Aggarwal R, Keenan BP. Oral Toxicities of PSMA-Targeted Immunotherapies for The Management of Prostate Cancer. Clinical genitourinary cancer. 2023. PMID: 38185609


Lawrence Fong, MD

Emperumal CP, Villa A, Hwang C, Oh D, Fong L, Aggarwal R, Keenan BP. Oral Toxicities of PSMA-Targeted Immunotherapies for The Management of Prostate Cancer. Clinical genitourinary cancer. 2023. PMID: 38185609


Rahul Aggarwal, MD

Emperumal CP, Villa A, Hwang C, Oh D, Fong L, Aggarwal R, Keenan BP. Oral Toxicities of PSMA-Targeted Immunotherapies for The Management of Prostate Cancer. Clinical genitourinary cancer. 2023. PMID: 38185609


David Oh, MD, PhD

Alan Paciorek, Farhana Moon, Le Bryan Khuong, Li Zhang, Paige Steiding, Emily Bergsland, Claire Mulvey. Rising incidence of bronchopulmonary neuroendocrine tumors. Endocrine Abstracts. 2023. PMID:


Claire Mulvey, MD

Yazdani A, Lenz HJ, Pillonetto G, Mendez-Giraldez R, Yazdani A, Sanof H, Hadi R, Samiei E, Venook AP, Ratain MJ, Rashid N, Vincent BG, Qu X, Wen Y, Kosorok M, Symmans WF, Shen JPYC, Lee MS, Kopetz S, Nixon AB, Bertagnolli MM, Perou CM, Innocenti F. Gene signatures derived from transcriptomic-causal networks stratified colorectal cancer patients for effective targeted therapy. Research square. 2023. PMID: 38168324


Alan Venook, MD

Zhu X, Koshkin VS. Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer. Med (New York, N.Y.). 2023. PMID: 38128535


Vadim Koshkin, MD

Le Bryan Khuong, Alan Paciorek, Farhana Moon, Heath Courtney Lawhn, Thomas Hope, Nicholas Fidelman, Claire Mulvey, Sheila Lindsay, Li Zhang¬, Eric Nakakura, Nancy Joseph, Emily K. Bergsland. Comparison of well-differentiated gastroenteropancreatic grade 3 neuroendocrine tumors (G3NETS): de novo and in the setting of apparent grade progression over time. Endocrine Abstracts. 2023. PMID:


Claire Mulvey, MD

Claire K. Mulvey, Alan Paciorek, Paige Steiding, Farhana Moon, Li Zhang, Emily K. Bergsland. Quality of life differs by age and sex for participants with advanced neuroendocrine neoplasms in the eNET study. Endocrine Abstracts. 2023. PMID:


Claire Mulvey, MD

Jhaveri K, O'Shaughnessy J, Fasching PA, Tolaney SM, Yardley DA, Sharma VK, Biswas C, Thuerigen A, Pathak P, Rugo HS. Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2- advanced breast cancer. Therapeutic advances in medical oncology. 2023. PMID: 38107828


Hope Rugo, MD

Van Loon K. Expert Commentary on Colon Cancer and the Pregnant Patient. Diseases of the colon and rectum. 2023. PMID: 38085013


Katherine Van Loon, MD, MPH

Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Magbanua MJ, Coppé JP, I-SPY 2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Pohlmann PR, Hirst GL, Esserman LJ, van 't Veer LJ, Petricoin EF. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial. Cell reports. Medicine. 2023. PMID: 38086377


Hope Rugo, MD

Weinstein HNW, Hu K, Fish L, Chen YA, Allegakoen P, Hui KSF, Pham JH, Baco MB, Song H, Giacomelli AO, Vazquez F, Ghandi M, Goodarzi H, Huang FW. RPL22 is a tumor suppressor in MSI-high cancers and a key splicing regulator of MDM4. bioRxiv : the preprint server for biology. 2023. PMID: 38106152


Franklin Huang, MD, PhD

Small EJ, Chi KN, Chowdhury S, Bevans KB, Bhaumik A, Saad F, Chung BH, Karsh LI, Oudard S, De Porre P, Brookman-May SD, McCarthy SA, Mundle SD, Uemura H, Smith MR, Agarwal N. Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer. European urology oncology. 2023. PMID: 38072759


Eric Small, MD

Cescon DW, Schmid P, Rugo HS, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Haiderali A, Zhou X, Guo Z, Nguyen AM, Cortes J. Health-Related Quality of Life With Pembrolizumab+Chemotherapy Versus Placebo+Chemotherapy for Advanced Triple-Negative Breast Cancer: KEYNOTE-355. Journal of the National Cancer Institute. 2023. PMID: 38070159


Hope Rugo, MD

Orme JJ, Taza F, De Sarkar N, Tewari AK, Arsalan Naqvi S, Riaz IB, Childs DS, Omar N, Adra N, Ashkar R, Cheng HH, Schweizer MT, Sokolova AO, Agarwal N, Barata P, Sartor O, Bastos D, Smaletz O, Berchuck JE, McClure H, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Mehra N, Nelson PS, Hwang J, Dehm SM, Shi Q, Fleischmann Z, Sokol ES, Elliott A, Huang H, Bryce A, Marshall CH, Antonarakis ES. Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. European urology oncology. 2023. PMID: 38072760


Rahul Aggarwal, MD

Van Loon K, Breithaupt L, Ng D, DeBoer RJ, Buckle GC, Bialous S, Hiatt RA, Volberding P, Hermiston ML, Ashworth A. A Roadmap to Establishing Global Oncology as a Priority Initiative within a National Cancer Institute-Designated Cancer Center. Journal of the National Cancer Institute. 2023. PMID: 38060289


Alan Ashworth, PhD

Myint KZ, Sueca-Comes M, Collier P, Balasubramanian B, Venkatraman S, Gordan J, Zaitoun AM, Mukherjee A, Arora A, Larbcharoensub N, Suriyonplengsaeng C, Wongprasert K, Janvilisri T, Gomez D, Grabowska AM, Tohtong R, Bates DO, Yacqub-Usman K. Preclinical evidence for anaplastic lymphoma kinase inhibitors as novel therapeutic treatments for cholangiocarcinoma. Frontiers in oncology. 2023. PMID: 38144528


John Gordan, MD, PhD

Van Loon K, Breithaupt L, Ng D, DeBoer RJ, Buckle GC, Bialous S, Hiatt RA, Volberding P, Hermiston ML, Ashworth A. A Roadmap to Establishing Global Oncology as a Priority Initiative within a National Cancer Institute-Designated Cancer Center. Journal of the National Cancer Institute. 2023. PMID: 38060289


Katherine Van Loon, MD, MPH

Van Loon K, Breithaupt L, Ng D, DeBoer RJ, Buckle GC, Bialous S, Hiatt RA, Volberding P, Hermiston ML, Ashworth A. A Roadmap to Establishing Global Oncology as a Priority Initiative within a National Cancer Institute-Designated Cancer Center. Journal of the National Cancer Institute. 2023. PMID: 38060289


Rebecca Deboer, MD, MA

Van Loon K, Breithaupt L, Ng D, DeBoer RJ, Buckle GC, Bialous S, Hiatt RA, Volberding P, Hermiston ML, Ashworth A. A Roadmap to Establishing Global Oncology as a Priority Initiative within a National Cancer Institute-Designated Cancer Center. Journal of the National Cancer Institute. 2023. PMID: 38060289


Geoffrey Buckle, MD, MPH